Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer
- 9 February 2016
- journal article
- review article
- Published by Elsevier BV in Clinical Gastroenterology and Hepatology
- Vol. 14 (5), 651-658
- https://doi.org/10.1016/j.cgh.2016.02.008
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancerThe Journal of Pathology, 2013
- Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic ValuePLoS Medicine, 2013
- A colorectal cancer classification system that associates cellular phenotype and responses to therapyNature Medicine, 2013
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon CancerJama-Journal Of The American Medical Association, 2012
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialThe Lancet, 2011
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisThe Lancet Oncology, 2010
- Deficient mismatch repair system in patients with sporadic advanced colorectal cancerBritish Journal of Cancer, 2009
- CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancerNature Genetics, 2006
- RAF/RAS oncogenes and mismatch-repair statusNature, 2002